Clinical Trials
3 trialsNCT05507632 2026-06-01
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Active not recruiting
NCT05890742 2026-05-28
A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Active not recruiting
NCT05201859 2026-05-07
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting